JPMorgan analyst Jessica Fye raised the firm’s price target on BioNTech (BNTX) to $121 from $116 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- CDC panel votes against requiring prescriptions for Covid shots, Bloomberg says
- Pfizer, BioNTech express dedication to making safe Covid vaccines
- CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says
- Trump Trade: Trump expected to extend deadline for TikTok sale
- Pfizer (PFE), Moderna (MRNA) Stocks Slide on Report Linking Child Deaths to COVID Vaccines